Nature Medicine reports today that the FDA's recent approval of Provenge, the first-ever cancer vaccine, could "open the floodgates" for other therapeutic vaccine treatments. The piece includes a list of ten promising cancer vaccines currently in mid- to late-stage development and quotes a biotech analyst as saying:
“[Provenge] finally breaks the glass ceiling after years of skepticism and many failures in the cancer immunotherapy space.”
As previously mentioned, Stanford pathologist Edgar Engleman, MD, played a vital role in the effort to develop the prostate-cancer vaccine. My colleague Ruthann Richter recently wrote about his work for Inside Stanford Medicine.